Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | CFD | P00746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21451620 | 0.85 | TSHR (0.47) | TSHRKAT6AHTTGRM2 | |
| SCHEMBL18891691 | 0.81 | CES2 (0.39) | TSHRCFDSMN1; SMN2 | |
| SCHEMBL23730871 | 0.81 | HTT (0.41) | TSHRHTTGRM2SMN1; SMN2 | |
| SCHEMBL22102746 | 0.81 | CFD (0.45) | CFD | |
| Hydrochloric Acid SCHEMBL16397363 | 0.79 | CFD (0.44) | CFD | |
| SCHEMBL17878038 | 0.77 | GABRA1 (0.44) | TSHRHTTSMN1; SMN2 | |
| SCHEMBL31381716 | 0.77 | GABRA1 (0.44) | TSHRHTTSMN1; SMN2 | |
| SCHEMBL21776119 | 0.76 | IDO1 (0.43) | — | |
| SCHEMBL20940100 | 0.76 | GABRA1 (0.39) | TSHR | |
| SCHEMBL22792362 | 0.76 | ADRB1 (0.32) | TSHRKAT6AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062760-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062760-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPRJ, PTPRC | TSHR 3514/4885KAT6A 944/4885HTT 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.